Acyclovir Dosing for HSV Meningitis

Dosing Recommendations

• The Infectious Diseases Society of America recommends that adults with HSV meningitis receive acyclovir at 10 mg/kg intravenously every 8 hours for 14-21 days with normal renal function 1, 2
• Treatment duration should be 14-21 days to ensure adequate viral suppression and prevent relapse, with a strength of evidence supporting early initiation of therapy to decrease mortality to 8% if treatment begins within 4 days of symptom onset 1, 2, 3
• Dose adjustments are necessary for patients with impaired renal function, with the strength of evidence indicating a need for careful monitoring and adjustment of acyclovir doses in patients with renal impairment 4

Clinical Considerations

• Distinguishing between HSV meningitis and encephalitis is crucial, as encephalitis represents a more severe condition requiring aggressive treatment, with the Centers for Disease Control and Prevention emphasizing the importance of prompt diagnosis and treatment 5
• In neonates, higher-dose acyclovir (20 mg/kg intravenously every 8 hours for 21 days) has shown improved outcomes with decreased mortality to 5%, based on evidence from the American Academy of Pediatrics 2, 3
• For severe cases requiring hospitalization, intravenous therapy is mandatory rather than oral alternatives, as recommended by the Centers for Disease Control and Prevention 6

Treatment Response Monitoring

• Consider obtaining a repeat CSF specimen for PCR at the end of therapy in patients who have not had appropriate clinical response, with the Infectious Diseases Society of America recommending this approach 2, 3
• If PCR remains positive for HSV at the end of treatment, antiviral therapy should be continued, based on evidence from the Infectious Diseases Society of America 2, 3
• Relapse of HSV infection has been reported after completion of acyclovir therapy, with rates as high as 5%, highlighting the need for ongoing monitoring and follow-up care 2, 3

Special Populations

Immunocompromised Patients

• Immunocompromised patients may require higher doses of antiviral medications, with the Centers for Disease Control and Prevention recommending careful consideration of dose adjustments in these patients 6
• For HIV-infected patients with severe HSV disease, acyclovir 5 mg/kg IV every 8 hours is recommended, based on guidelines from the Centers for Disease Control and Prevention 6
• If acyclovir resistance is suspected (persistent lesions despite therapy), alternative treatments such as foscarnet (40 mg/kg IV every 8 hours) should be considered, with the Centers for Disease Control and Prevention emphasizing the importance of prompt recognition and management of resistance 6

Potential Complications and Monitoring

• Monitor renal function throughout treatment, as acyclovir can cause nephrotoxicity, with the Infectious Diseases Society of America recommending regular monitoring of renal function in patients receiving acyclovir 4

Acyclovir Dosing for Viral Meningitis

Age-Based Dosing Recommendations

• The standard dosing regimen for children 3 months-12 years achieves therapeutic plasma concentrations while minimizing toxicity, with a recommended dose of 500 mg/m² IV every 8 hours 7, 8, 9
• For adolescents >12 years, the recommended dose is 10 mg/kg IV every 8 hours, which achieves therapeutic plasma concentrations while minimizing toxicity 7, 8, 9

Critical Distinction: Meningitis vs. Encephalitis

• The guidelines primarily address encephalitis, but the dosing translates to meningitis management, with encephalitis involving altered mental status, focal neurological deficits, and parenchymal brain involvement requiring more aggressive treatment 7, 8
• For suspected encephalitis, acyclovir should be started within 6 hours of admission, even if initial CSF or imaging is normal, to ensure adequate viral suppression and prevent relapse 7, 8, 9

Dose Adjustments for Renal Impairment

• Acyclovir must be dose-adjusted in patients with impaired renal function, as the drug is 62-91% renally excreted, with monitoring of renal function throughout treatment to prevent nephrotoxicity 7, 8
• Reduce dose based on creatinine clearance to prevent crystalluria and obstructive nephropathy, with maintenance of adequate hydration to reduce nephrotoxicity risk 7, 8

Common Pitfalls to Avoid

• Do not use oral acyclovir for acute viral meningitis requiring hospitalization - IV therapy is mandatory for severe cases, as recommended by the Centers for Disease Control and Prevention 10

Adverse Effects Monitoring

• Nephrotoxicity manifests after 4 days of IV therapy in up to 20% of patients; monitor creatinine and maintain hydration to prevent nephrotoxicity 7, 8
• Rare adverse events include hepatitis, bone marrow suppression, and encephalopathy, which can be minimized with proper dosing and monitoring 7, 8

Acyclovir Treatment for HSV Meningitis

Introduction to Acyclovir Dosing

• The American Academy of Neurology recommends that patients with HSV encephalitis receive acyclovir 10 mg/kg IV every 8 hours, which is the same dose used for HSV meningitis, but encephalitis is a more severe condition with altered mental status and parenchymal brain involvement, and has mortality rates of 70% without treatment versus 20-30% with acyclovir 11

Treatment Monitoring and Initiation

• The Infectious Diseases Society of America suggests that CSF PCR remains positive for 7-10 days after starting treatment, so delayed lumbar puncture can still confirm diagnosis, and early treatment (within 4 days of symptom onset) reduces mortality to 8% compared to 28% with delayed treatment 11, 12
• The Centers for Disease Control and Prevention recommend considering repeat CSF PCR at 14-21 days in patients without appropriate clinical response; if still positive, continue antiviral therapy 11, 12

Hydration and Nephrotoxicity Prevention

• The European Society of Clinical Microbiology and Infectious Diseases advises maintaining adequate hydration throughout treatment as acyclovir can cause crystalluria and obstructive nephropathy in up to 20% of patients, typically manifesting after 4 days of IV therapy 11, 12

Common Pitfalls to Avoid

• The American College of Physicians recommends never using oral acyclovir for acute HSV meningitis—IV therapy is mandatory for CNS infections as oral formulations do not achieve adequate CSF levels 11, 12
• The Infectious Diseases Society of America suggests not stopping treatment prematurely—the original 10-day regimens led to relapse rates of 26-29% in children, which is why current guidelines recommend 14-21 days 11, 12

Special Populations

• The Centers for Disease Control and Prevention recommend that immunocompromised patients may require prolonged courses beyond 21 days if CSF PCR remains positive, and if acyclovir resistance is suspected, consider foscarnet 40 mg/kg IV every 8 hours as alternative 13, 14
• The American Academy of Pediatrics suggests that neonates with HSV CNS disease should receive 20 mg/kg IV every 8 hours for 21 days, which is a higher dose due to worse outcomes in this age group 14